Drug composition

Abstract

The present invention provides an injectable ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate formulation. The formulation contains ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate, a suspending agent, a stabilizer, an osmotic pressure adjusting agent, a pH adjusting agent, and a solvent. The formulation may be a ready-to-use liquid injectable formulation or a lyophilized powder injectable formulation. The formulation has a clear sustained-release effect after injection, which can extend the drug's duration of action, reduce the number of doses, improve patient compliance, and improve bioavailability. The present invention also provides a method for preparing the injectable ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate formulation, which is simple, economical, and suitable for industrial production.

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical preparations, and particularly to a methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate injection preparation.

Background Art

[0002] Alzheimer's disease (abbreviated as AD) is one of the diseases commonly seen in the elderly, and is a chronic neurodegenerative disease characterized by main clinical features such as memory decline and cognitive dysfunction. As the aging of the population accelerates, the incidence of this disease continues to increase. Among people over 80 years old, about 20% suffer from Alzheimer's disease. According to the degree of clinical deterioration of cognitive function and physical function, it can be divided into three stages: the first stage (1 - 3 years, mild dementia), the second stage (2 - 10 years, moderate dementia), and the third stage (8 - 12 years, severe dementia). Patients with severe dementia are completely dependent on others, have severe memory loss, are unable to take care of themselves in daily life, have defecation and urination disorders, are silent, have limb rigidity, show positive pyramidal tract signs during physical examination, have primitive reflexes such as grasping, groping, and sucking, and ultimately may fall into a coma and cause infections and other problems leading to death. Due to problems with memory, judgment, and thinking ability, patients have a reduced ability to take care of themselves in life and suffer great mental pain. In addition, due to the long disease duration of this disease, the burden on society and families is significantly increased.

[0003] Memantine is an excitatory amino acid receptor antagonist used in the treatment of moderate to severe Alzheimer's type dementia. Currently, memantine hydrochloride tablets, memantine hydrochloride solutions, and memantine hydrochloride sustained-release capsules for oral administration are sold at home and abroad. These dosage forms have a short maintenance time of drug blood concentration, require frequent administration, increase patient non-compliance and side effects, and due to the influence of patients' cognitive impairment and other symptoms, the ability to actively take medication is reduced, often leading to treatment failure.

Summary of the Invention

[0004] Currently, sustained-release injectable formulations of memantine (chemical name: 1-amino-3,5-dimethyladamantylamine, whose structure is represented by formula C below) and its salts or esters are not commercially available, and prior art lacks research on non-enteral administration formulations of memantine and its salts. ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate, whose structure is represented by formula A below, is a prodrug obtained by esterification modification of memantine. Compared to memantine hydrochloride (chemical name: 1-amino-3,5-dimethyladamantylamine hydrochloride, whose structure is represented by formula B below), this compound has significantly lower solubility and is almost insoluble in water. The gradual dissolution of the drug into tissue sites slows down the rate at which the drug enters the bloodstream, achieving a sustained-release effect in the body and achieving the goal of sustained treatment. [ka] [Means for solving the problem]

[0005] A first aspect of the present invention provides a ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation. In the formulation according to the present invention, ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is highly concentrated, has a controllable particle size, and can achieve a high dose in a limited injection volume and a sustained drug release effect. The formulation may be stored in the form of a suspension in a pre-filled syringe or in the form of a lyophilized powder in a vial. The former can be used directly, and the latter can be mixed with sterile water for injection to prepare a suspension for use by intramuscular or subcutaneous injection. Compared to memantine oral tablets, the formulation according to the present invention has the following advantages: (1) APIs (active pharmaceutical ingredients) in suspension exist as insoluble particles, have low solubility, and exhibit a clear sustained-release effect after drug injection, significantly reducing the number of administrations, extending the duration of drug action, and improving patient compliance. (2) The above-mentioned preparation has a high drug load and can provide a dose for at least one week. (3) The API in the suspension has controllable particle size and high injectability, (4) The suspension, after freeze-drying, is highly stable and suitable for storage and transport. (5) The above formulations have stable drug release and can avoid fluctuations in clinical indicators due to missed doses.

[0006] A second aspect of the present invention provides a method for preparing the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation described in the present invention. The preparation method according to the present invention is simple, easy to perform, highly stable and safe, and suitable for industrial production. In the above preparation method, a lyophilization step can be further added to prepare a lyophilized formulation of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate.

[0007] A third aspect of the present invention provides the use of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation in the preparation of drugs for treating Alzheimer's disease. Definition of Terms

[0008] This invention is intended to cover all alternatives, modifications, and equivalents, all of which fall within the scope of the invention as defined by the claims. Those skilled in the art should recognize that various methods and materials similar or equivalent to those described herein may be used to carry out the invention. The invention is not limited to the methods and materials described herein. In the event that one or more of the referenced documents, patents, or similar materials differ from or conflict with this application (including, but not limited to, defined terms, terminology, or described techniques), this application shall prevail.

[0009] For clarity, some features of the present invention will be described in multiple independent embodiments, but they may also be provided as a combination in a single embodiment. Conversely, for convenience, various features of the present invention will be described in a single embodiment, but they may also be provided individually or as any appropriate sub-combination.

[0010] Unless otherwise specified, all scientific terms used in this invention have the same meaning as those commonly understood by those skilled in the art. All patents and published works relating to this invention are incorporated collectively by reference.

[0011] The terms "contains" or "includes" are open expressions, meaning they include the contents explicitly stated in this invention, but do not exclude other contents.

[0012] In the context of the present invention, all numbers disclosed herein are approximations, whether or not the words “about” or “approximately” are used. Based on the disclosed figures, the value of each number may vary by ±10%, such as ±1%, ±2%, ±3%, ±4%, or ±5%, or by a difference that is reasonable when considered by those skilled in the art.

[0013] The term "D[4,3]" refers to the volume-weighted average value measured with a Malvern Mastersizer 3000 laser particle size analyzer.

[0014] The term "Dv10" refers to the particle size at which the cumulative percentage of the particle size-volume distribution of a single sample reaches 10%, the term "Dv50" refers to the particle size at which the cumulative percentage of the particle size-volume distribution of a single sample reaches 50%, and the term "Dv90" refers to the particle size at which the cumulative percentage of the particle size-volume distribution of a single sample reaches 90%.

[0015] LC / MS / MS refers to liquid chromatography-mass spectrometry.

[0016] "Sustained-release" refers to the ability to detect the drug blood concentration of memantine (1-amino-3,5-dimethyladamantylamine) by detecting the sample with an LC / MS / MS analyzer, depending on the detection limit.

[0017] The concentration "mg / mL" refers to milligrams per milliliter, which is weight per volume. The volume mentioned above is the volume of the suspension, including the suspension before freeze-drying or the suspension after freeze-drying and subsequent redissolution.

[0018] μm stands for micrometer, μL for microliter, L for liter, mm for millimeter, mL for milliliter, nm for nanometer, ng for nanogram, kg for kilogram, min for minute, d for day, Hz for Hertz, g for gram, qs for appropriate amount, mbar for millibar, V for volt, and °C for degrees Celsius. Detailed description of the invention

[0019] After diligent research and consideration to address the shortcomings of prior art, the present invention provides an injectable formulation containing ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate. The formulation according to the present invention may be in the form of a suspension or in the form of a lyophilized powder. The former can be used directly, while the latter is used by mixing with sterile water for injection to prepare a suspension, and is administered by intramuscular or subcutaneous injection. Compared to memantine oral tablets, the formulation according to the present invention has a higher drug load, can gradually and sustainably release the drug after injection, can sustain the release for at least one week or more, can significantly reduce the number of administrations, and can improve patient treatment compliance and safety by avoiding peak-trough fluctuations. The injectable formulation according to the present invention is highly stable and convenient for storage and transport. Furthermore, when the above formulation is in the form of a suspension, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate in the suspension has controllable particle size, high injectability, and is advantageous for improving its bioavailability.

[0020] The ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation according to the present invention may have a Dv50 range of 1.0 μm to 20.0 μm for the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate. In some embodiments, the Dv50 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 1.0 μm to 15.0 μm or 1.0 μm to 10.0 μm or 1.0 μm to 5.0 μm or 1.0 μm to 2.0 μm or 1.0 μm to 3.0 μm or 1.0 μm to 4.0 μm or 1.0 μm to 6.0 μm or 1.0 μm to 7.0 μm or 1.0 μm to 8.0 μm or 2.0 μm to 5.0 μm or 2.0 μm to 8.0 μm or 5.0 μm to 8.0 μm or 8.0 μm to 15.0 μm. In some examples, the Dv50 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 5.0 μm to 10.0 μm. In some examples, the Dv50 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 5.0 μm to 15.0 μm. In some examples, the Dv50 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 5.0 μm to 20.0 μm. In some embodiments, the Dv50 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 10.0 μm to 15.0 μm. In some embodiments, the Dv50 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 10.0 μm to 20.0 μm. In some embodiments, the Dv50 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 15.0 μm to 20.0 μm.In some embodiments, the Dv50 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 3.0 μm to 7.0 μm.

[0021] In the aforementioned ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation, the Dv10 range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate may be 0.1 μm to 5.0 μm. In some embodiments, the Dv10 range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 1.0 μm to 3.0 μm. In some examples, the Dv10 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 1.0 μm to 2.0 μm. In some examples, the Dv10 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 1.0 μm to 3.0 μm. In some examples, the Dv10 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 1.0 μm to 5.0 μm. In some examples, the Dv10 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 2.0 μm to 3.0 μm. In some examples, the Dv10 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 2.0 μm to 5.0 μm. In some examples, the Dv10 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 3.0 μm to 5.0 μm.

[0022] In the aforementioned ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation, the Dv90 range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate may be 5.0 μm to 60.0 μm. In some embodiments, the Dv90 range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 5.0 μm to 20.0 μm. In some examples, the Dv90 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 5.0 μm to 10.0 μm. In some examples, the Dv90 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 5.0 μm to 30.0 μm. In some examples, the Dv90 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 10.0 μm to 20.0 μm. In some examples, the Dv90 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 10.0 μm to 30.0 μm. In some examples, the Dv90 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 10.0 μm to 60.0 μm. In some examples, the Dv90 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 20.0 μm to 30.0 μm. In some examples, the Dv90 range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 20.0 μm to 60.0 μm.In some embodiments, the Dv90 range of methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate is 30.0 μm to 60.0 μm.

[0023] In some embodiments, in the methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate injection preparation according to the present invention, the Dv50 range of the methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate is 1.0 μm to 20.0 μm, the Dv10 range is 0.1 μm to 5.0 μm, and the Dv90 range is 5.0 μm to 60.0 μm.

[0024] In the aforementioned ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation, the D[4,3] range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate may be 1.0 μm to 30.0 μm. In some embodiments, the D[4,3] range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 3.0 μm to 20.0 μm. In some examples, the D[4,3] range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 1.0 μm to 5.0 μm. In some examples, the D[4,3] range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 1.0 μm to 10.0 μm. In some examples, the D[4,3] range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 1.0 μm to 20.0 μm. In some examples, the D[4,3] range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 5.0 μm to 10.0 μm. In some examples, the D[4,3] range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 5.0 μm to 20.0 μm. In some examples, the D[4,3] range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 5.0 μm to 30.0 μm. In some examples, the D[4,3] range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 10.0 μm to 20.0 μm.In some embodiments, the D[4,3] range of methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate is 10.0 μm to 30.0 μm. In some embodiments, the D[4,3] range of methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate is 20.0 μm to 30.0 μm.

[0025] In some embodiments, in the methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate injection preparation according to the present invention, the Dv50 range of methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate is 1.0 μm to 20.0 μm, the Dv10 range is 0.1 μm to 5.0 μm, the Dv90 range is 5.0 μm to 60.0 μm, and the D[4,3] range is 1.0 μm to 30.0 μm.

[0026] The methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate injection preparation according to the present invention contains methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate and a carrier.

[0027] In some embodiments, the methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate injection preparation according to the present invention (a) methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate, (b) a carrier, (c) water for injection.

[0028] In some embodiments, the methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate injection preparation (a) Methyl benzoate ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy) having a concentration range of 105.0 mg / mL to 300.0 mg / mL, (b) A carrier and, optionally, (c) Water for injection, and, The aforementioned formulation sustains the release of memantine for a period of at least one week.

[0029] The carrier comprises at least one selected from stabilizers, suspending agents, pH adjusters, osmotic pressure adjusters, and freeze-drying protective agents.

[0030] In some embodiments, the carrier comprises a stabilizer and / or a suspending agent and / or an osmotic pressure modifier and / or a freeze-drying protective agent and / or a pH adjuster.

[0031] The ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation described in the present invention may contain a stabilizer.

[0032] The concentration range of the stabilizer may be 5.0 mg / mL to 48.0 mg / mL. In some embodiments, the concentration of the stabilizer is 10.0 mg / mL to 35.0 mg / mL. In some examples, the concentration range of the stabilizer is 6.0 mg / mL to 10.0 mg / mL. In some examples, the concentration range of the stabilizer is 6.0 mg / mL to 15.0 mg / mL. In some examples, the concentration range of the stabilizer is 6.0 mg / mL to 20.0 mg / mL. In some examples, the concentration range of the stabilizer is 6.0 mg / mL to 30.0 mg / mL. In some examples, the concentration range of the stabilizer is 6.0 mg / mL to 35.0 mg / mL. In some examples, the concentration range of the stabilizer is 10.0 mg / mL to 15.0 mg / mL. In some examples, the concentration range of the stabilizer is 10.0 mg / mL to 20.0 mg / mL. In some examples, the concentration range of the stabilizer is 10.0 mg / mL to 30.0 mg / mL. In some examples, the concentration range of the stabilizer is 10.0 mg / mL to 35.0 mg / mL. In some examples, the concentration range of the stabilizer is 10.0 mg / mL to 48.0 mg / mL. In some examples, the concentration range of the stabilizer is 15.0 mg / mL to 20.0 mg / mL. In some examples, the concentration range of the stabilizer is 15.0 mg / mL to 30.0 mg / mL. In some examples, the concentration range of the stabilizer is 15.0 mg / mL to 35.0 mg / mL. In some examples, the concentration range of the stabilizer is 15.0 mg / mL to 48.0 mg / mL. In some examples, the concentration range of the stabilizer is 20.0 mg / mL to 30.0 mg / mL. In some examples, the concentration range of the stabilizer is 20.0 mg / mL to 35.0 mg / mL. In some examples, the concentration range of the stabilizer is 20.0 mg / mL to 48.0 mg / mL. In some examples, the concentration range of the stabilizer is 30.0 mg / mL to 35.0 mg / mL. In some examples, the concentration range of the stabilizer is 30.0 mg / mL to 48.0 mg / mL.In some examples, the concentration range of the stabilizer is 35.0 mg / mL to 48.0 mg / mL. In some examples, the concentration range of the stabilizer is 5.0 mg / mL to 25.0 mg / mL. In some examples, the concentration of the stabilizer is 7.9 mg / mL, 14.5 mg / mL, 15.0 mg / mL, 17.0 mg / mL, 20.0 mg / mL, 30.0 mg / mL, or 35.0 mg / mL.

[0033] The stabilizer comprises at least one selected from polysorbate 20, polysorbate 60, polysorbate 80, span 20, lecithin, poloxamer 188, poloxamer 338, poloxamer 407, and polyoxyl 15 hydroxystearate. In some examples, the stabilizer is polysorbate 80. In some examples, the stabilizer is a mixture of polysorbate 80 and span 20. In some examples, the stabilizer is a mixture of polysorbate 20 and span 20. In some examples, the stabilizer is poloxamer 338. In some examples, the stabilizer is poloxamer 188.

[0034] The concentration range of the polysorbate 80 may be 2.0 mg / mL to 30.0 mg / mL. In some embodiments, the concentration of the polysorbate 80 is 5.0 mg / mL to 30.0 mg / mL or 5.0 mg / mL to 15.0 mg / mL or 10.0 mg / mL to 20.0 mg / mL. In some examples, the concentration range of the polysorbate 80 is 5.0 mg / mL to 10.0 mg / mL. In some examples, the concentration range of the polysorbate 80 is 5.0 mg / mL to 20.0 mg / mL. In some examples, the concentration range of the polysorbate 80 is 10.0 mg / mL to 15.0 mg / mL. In some examples, the concentration range of the polysorbate 80 is 10.0 mg / mL to 30.0 mg / mL. In some examples, the concentration range of polysorbate 80 is 15.0 mg / mL to 20.0 mg / mL. In some examples, the concentration range of polysorbate 80 is 15.0 mg / mL to 30.0 mg / mL. In some examples, the concentration range of polysorbate 80 is 20.0 mg / mL to 30.0 mg / mL. In some examples, the concentration of polysorbate 80 is 5.5 mg / mL, 10.0 mg / mL, 15.0 mg / mL, 20.0 mg / mL, or 30.0 mg / mL.

[0035] The concentration range of the span 20 may be 0 mg / mL to 15.0 mg / mL. In some embodiments, the concentration of the span 20 is 2.5 mg / mL to 10.0 mg / mL or 5.0 mg / mL to 12.5 mg / mL. In some examples, the concentration range of the span 20 is 1.0 mg / mL to 2.5 mg / mL. In some examples, the concentration range of the span 20 is 1.0 mg / mL to 5.0 mg / mL. In some examples, the concentration range of the span 20 is 1.0 mg / mL to 10.0 mg / mL. In some examples, the concentration range of the span 20 is 1.0 mg / mL to 12.5 mg / mL. In some examples, the concentration range of the span 20 is 2.5 mg / mL to 5.0 mg / mL. In some examples, the concentration range of the span 20 is 2.5 mg / mL to 12.5 mg / mL. In some examples, the concentration range of span 20 is 2.5 mg / mL to 18.0 mg / mL. In some examples, the concentration range of span 20 is 5.0 mg / mL to 10.0 mg / mL. In some examples, the concentration range of span 20 is 5.0 mg / mL to 18.0 mg / mL. In some examples, the concentration range of span 20 is 10.0 mg / mL to 12.5 mg / mL. In some examples, the concentration range of span 20 is 10.0 mg / mL to 18.0 mg / mL. In some examples, the concentration of span 20 is 2.5 mg / mL or 5.0 mg / mL.

[0036] In some embodiments, the stabilizer is a mixture of polysorbate 80 and span 20, and the ratio of the concentrations of polysorbate 80 to span 20 is in the range of 1:1 to 6:1. In some examples, the ratio of the concentrations of polysorbate 80 to span 20 is 2:1, in some examples, the ratio of the concentrations of polysorbate 80 to span 20 is 2.4:1, in some examples, the ratio of the concentrations of polysorbate 80 to span 20 is 3:1, in some examples, the ratio of the concentrations of polysorbate 80 to span 20 is 4:1, in some examples, the ratio of the concentrations of polysorbate 80 to span 20 is 4.8:1, and in some examples, the ratio of the concentrations of polysorbate 80 to span 20 is 6:1.

[0037] The ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation described in the present invention may further contain a suspension.

[0038] The concentration range of the suspension may be 0.35 mg / mL to 125.0 mg / mL. In some embodiments, the concentration range of the suspension is 40.0 mg / mL to 100.0 mg / mL or 50.0 mg / mL to 120.0 mg / mL. In some examples, the concentration range of the suspension is 40.0 mg / mL to 60.0 mg / mL. In some examples, the concentration range of the suspension is 40.0 mg / mL to 80.0 mg / mL. In some examples, the concentration range of the suspension is 40.0 mg / mL to 125.0 mg / mL. In some examples, the concentration range of the suspension is 60.0 mg / mL to 80.0 mg / mL. In some examples, the concentration range of the suspension is 60.0 mg / mL to 100.0 mg / mL. In some examples, the concentration range of the suspension is 60.0 mg / mL to 125.0 mg / mL. In some examples, the concentration range of the suspension is 80.0 mg / mL to 100.0 mg / mL. In some examples, the concentration range of the suspension is 80.0 mg / mL to 125.0 mg / mL. In some examples, the concentration range of the suspension is 100.0 mg / mL to 125.0 mg / mL. In some examples, the concentration range of the suspension is 0.35 mg / mL to 2.0 mg / mL. In some examples, the concentration range of the suspension is 0.35 mg / mL to 5.0 mg / mL. In some examples, the concentration range of the suspension is 0.35 mg / mL to 20.0 mg / mL. In some examples, the concentration of the suspension is 10.0 mg / mL, 40.0 mg / mL, 60.0 mg / mL, 80.0 mg / mL, or 100.0 mg / mL.

[0039] The suspension agent comprises at least one selected from dextran, gelatin, hypromellose, methylcellulose, gum arabic, polyethylene glycol 3350, polyethylene glycol 4000, polyethylene glycol 6000, sodium carboxymethylcellulose, and polyvinylpyrrolidone. In some examples, the suspension agent is polyethylene glycol 4000, in some examples, the suspension agent is polyethylene glycol 3350, in some examples, the suspension agent is polyethylene glycol 6000, and in some examples, the suspension agent is sodium carboxymethylcellulose. In some examples, the suspension agent is polyvinylpyrrolidone K12, and in some examples, the suspension agent is polyvinylpyrrolidone K30.

[0040] In some embodiments, the concentration range of polyethylene glycol 4000 as a suspension agent is 35.0 mg / mL to 125.0 mg / mL. In some examples, the concentration range of polyethylene glycol 4000 as a suspension agent is 50.0 mg / mL to 120.0 mg / mL. In some examples, the concentration range of polyethylene glycol 4000 as a suspension agent is 40.0 mg / mL to 60.0 mg / mL. In some examples, the concentration range of polyethylene glycol 4000 as a suspension agent is 40.0 mg / mL to 80.0 mg / mL. In some examples, the concentration range of polyethylene glycol 4000 as a suspension agent is 40.0 mg / mL to 125.0 mg / mL. In some examples, the concentration range of polyethylene glycol 4000 as a suspension agent is 60.0 mg / mL to 80.0 mg / mL. In some examples, the concentration range of polyethylene glycol 4000 as a suspension agent is 60.0 mg / mL to 100.0 mg / mL. In some examples, the concentration range of polyethylene glycol 4000 as a suspension agent is 60.0 mg / mL to 125.0 mg / mL. In some examples, the concentration range of polyethylene glycol 4000 as a suspension agent is 80.0 mg / mL to 100.0 mg / mL. In some examples, the concentration range of polyethylene glycol 4000 as a suspension agent is 80.0 mg / mL to 125.0 mg / mL. In some examples, the concentration range of polyethylene glycol 4000 as a suspension agent is 100.0 mg / mL to 125.0 mg / mL. In some examples, the concentration of polyethylene glycol 4000 as a suspension agent is 40.0 mg / mL, 60.0 mg / mL, 80.0 mg / mL, or 100.0 mg / mL.

[0041] The ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation described in the present invention may further contain a pH adjuster.

[0042] The pH adjusting agent comprises at least one selected from hydrochloric acid, sodium hydroxide, phosphoric acid and its salts, tartaric acid and its salts, acetic acid and its salts, citric acid and its salts, and carbonic acid and its salts. In some examples, the pH adjusting agent is sodium hydroxide; in some examples, the pH adjusting agent is phosphoric acid and its salts; and in some examples, the pH adjusting agent is citric acid and its salts.

[0043] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation comprises a stabilizer and a suspension agent.

[0044] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation comprises a suspension agent and a pH adjuster.

[0045] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation contains stabilizers and pH adjusters.

[0046] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation comprises a stabilizer, a suspending agent, and a pH adjuster.

[0047] The ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation described in the present invention may contain an osmotic pressure modifier.

[0048] The ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation described in the present invention may contain a lyophilized protective agent.

[0049] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation comprises a stabilizer and / or a suspending agent and / or an osmotic pressure modifier and / or a lyophilization protective agent and / or a pH adjuster.

[0050] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation comprises a stabilizer and / or a suspending agent.

[0051] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation comprises a stabilizer, a suspending agent, a pH adjuster, and an osmotic pressure adjuster.

[0052] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation comprises a stabilizer, a suspending agent, an osmotic pressure modifier, and a lyophilization protective agent.

[0053] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation comprises a stabilizer, a suspending agent, and a pH adjuster.

[0054] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation contains stabilizers and osmotic pressure modifiers.

[0055] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation comprises a stabilizer, a suspending agent, and an osmotic pressure modifier.

[0056] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation comprises a stabilizer, a suspending agent, and a lyophilization protective agent.

[0057] The osmotic pressure adjusting agent comprises at least one selected from anhydrous disodium hydrogen phosphate, citric acid monohydrate, sodium chloride, glucose, glycerin, and citric acid.

[0058] The freeze-drying protective agent comprises at least one selected from polyethylene glycol 3350, polyethylene glycol 4000, mannitol, sorbitol, glucose, sucrose, lactose, dextran, trehalose, and glycine. In some examples, the freeze-drying protective agent is polyethylene glycol 3350. In some examples, the freeze-drying protective agent is polyethylene glycol 4000.

[0059] The concentration range of the lyophilization protective agent may be 50.0 mg / mL to 150.0 mg / mL. In some examples, the concentration range of the lyophilization protective agent is 80.0 mg / mL to 125.0 mg / mL. In some examples, the concentration range of the lyophilization protective agent is 50.0 mg / mL to 80.0 mg / mL, in some examples, the concentration range of the lyophilization protective agent is 50.0 mg / mL to 100.0 mg / mL, in some examples, the concentration range of the lyophilization protective agent is 50.0 mg / mL to 125.0 mg / mL, in some examples, the concentration range of the lyophilization protective agent is 80.0 mg / mL to 100.0 mg / mL, and In several examples, the concentration range of the freeze-drying protective agent is 80.0 mg / mL to 150.0 mg / mL, in some examples the concentration range of the freeze-drying protective agent is 100.0 mg / mL to 125.0 mg / mL, in some examples the concentration range of the freeze-drying protective agent is 100.0 mg / mL to 150.0 mg / mL, and in some examples the concentration range of the freeze-drying protective agent is 125.0 mg / mL to 150.0 mg / mL. In some examples the concentration of the freeze-drying protective agent is 80.0 mg / mL, 90.0 mg / mL, 100.0 mg / mL, or 125.0 mg / mL.

[0060] The ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation described in the present invention has a high drug load, and the concentration range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate may be 105.0 mg / mL to 300.0 mg / mL. In some examples, the concentration range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate in the injection formulation is 125.0 mg / mL to 250.0 mg / mL. In some examples, the concentration range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 105.0 mg / mL to 150.0 mg / mL.In some examples, the concentration range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 105.0 mg / mL to 200.0 mg / mL, and in some examples, the concentration range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 105.0 mg / mL to 250.0 mg / mL. In some examples, the concentration range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 150.0 mg / mL to 200.0 mg / mL, and in some examples, the concentration range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 150.0 mg / mL to 250.0 mg / mL. In some examples, the concentration range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 150.0 mg / mL to 300.0 mg / mL, and in some examples, the concentration range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 200.0 mg / mL to 250.0 mg / mL. In some examples, the concentration range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 200.0 mg / mL to 300.0 mg / mL, and in some examples, the concentration range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 250.0 mg / mL to 300.0 mg / mL. In some examples, the concentration of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate in the injectable formulation is 100 mg / mL, 125 mg / mL, 150.0 mg / mL, 200.0 mg / mL, 250.0 mg / mL, or 300.0 mg / mL.In some embodiments, the concentration of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate in the injectable formulation is 125.0 mg / mL, which is advantageous in obtaining a formulation with high bioavailability.

[0061] The pH range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation described in the present invention may be 6.0 to 9.0. In some examples, the pH range of the formulation is 6.5 to 7.5 or 6.5 to 8.0 or 7.0 to 8.0 or 6.0 to 7.0. In some examples, the pH range of the formulation is 7.0 to 7.5. In some examples, the pH range of the formulation is 6.5 to 7.0.

[0062] The ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation described in the present invention sustains memantine release for at least one week after injection.

[0063] The ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation described in the present invention may be in the form of a suspension, the Dv50 range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate being 1.0 μm to 20.0 μm, and the preparation sustainably releases memantine for a period of at least 2 weeks, up to 4 weeks or more, for example, up to 6 weeks.

[0064] The ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation described in the present invention may be in the form of a suspension, and the concentration range of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is 105.0 mg / mL to 300.0 mg / mL, and the preparation sustainably releases memantine for a period of at least 2 weeks, up to 4 weeks or more, for example, up to 6 weeks.

[0065] The ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation described in the present invention may be a ready-to-use liquid injection preparation or a lyophilized preparation, the lyophilized preparation of which needs to be redissolved in sterile water for injection before use. In some examples, it is a ready-to-use liquid injection preparation, and in some examples, it is a lyophilized powder injection preparation.

[0066] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation is a lyophilized formulation in the form of a cake.

[0067] In some embodiments, the pH range of the lyophilized ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)methyl benzoate preparation may be 6.0 to 9.0. In some examples, the pH range of the lyophilized ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)methyl benzoate preparation is 6.5 to 7.5 or 6.5 to 8.0 or 7.0 to 8.0 or 6.0 to 7.0. In some examples, the pH range of the lyophilized ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)methyl benzoate preparation is 7.0 to 7.5. In some examples, the pH range of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate lyophilized preparation is 6.5 to 7.0.

[0068] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation is (a)((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate, (b) A stabilizer selected from polysorbate 80, poloxamer 188, poloxamer 338, poloxamer 407, and a mixture of polysorbate 80 and span 20, and / or (c) comprising a suspending agent selected from polyethylene glycol 4000, polyethylene glycol 3350, sodium carboxymethylcellulose, and polyvinylpyrrolidone.

[0069] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation is (a) Methyl benzoate ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy) having a concentration range of 105.0 mg / mL to 300.0 mg / mL, (b) A stabilizer selected from polysorbate 80, poloxamer 188, poloxamer 338, poloxamer 407, and a mixture of polysorbate 80 and span 20, with a concentration range of 5.0 mg / mL to 48.0 mg / mL, and / or (c) A suspension selected from polyethylene glycol 4000, polyethylene glycol 3350, sodium carboxymethylcellulose, and polyvinylpyrrolidone, with a concentration range of 0.35 mg / mL to 125.0 mg / mL, comprising:

[0070] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation is (a) Methyl benzoate ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy) having a concentration range of 105.0 mg / mL to 300.0 mg / mL, (b) A mixture of polysorbate 80 and span 20 having a concentration range of 6.0 mg / mL to 48.0 mg / mL, and / or (c) Polyethylene glycol 4000 having a concentration range of 35.0 mg / mL to 125.0 mg / mL, Optionally, it may contain a pH adjuster.

[0071] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation is (a) Methyl benzoate ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy) having a concentration range of 125.0 mg / mL to 250.0 mg / mL, (b) Polyethylene glycol 4000 having a concentration range of 50.0 mg / mL to 120.0 mg / mL, and / or (c) A mixture of polysorbate 80 and span 20 having a concentration range of 5.0 mg / mL to 25.0 mg / mL, Optionally, it may contain a pH adjuster.

[0072] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation is (a) Methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate with a concentration of 125.0 mg / mL, (b) A mixture of polysorbate 80 and span 20 with a concentration of 8.0 mg / mL (c) Contains polyethylene glycol 4000 with a concentration of 100.0 mg / mL.

[0073] In some embodiments, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation is (a) Methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate with a concentration of 250.0 mg / mL, (b) A mixture of polysorbate 80 and span 20 with a concentration of 25.0 mg / mL, (c) Contains polyethylene glycol 4000 with a concentration of 120.0 mg / mL.

[0074] In another aspect, the present invention provides a method for preparing any of the above-described ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulations.

[0075] The method for preparing the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation is as follows: (a) A step of mixing the stabilizer with water and optionally adding a suspension agent, (b) The step of adding ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a suspension, (c) Optionally, adjust the pH with a pH adjuster and bring to a fixed volume. (d) The step of grinding the above suspension to obtain a final suspension.

[0076] In some examples, the method for preparing the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation is (a) A step of mixing the stabilizer and suspension agent with water, and optionally adding a pH adjuster and an osmotic pressure adjuster, (b) The step of adding ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a suspension, (c) Optionally, adjust the pH to 6.0-9.0 with a pH adjusting agent and then bring to a final volume. (d) The step of grinding the above suspension to obtain a final suspension.

[0077] In some embodiments, the suspension is ground using a ball mill.

[0078] In some examples, the method for preparing the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation is (a) Mix polysorbate 80 and span 20 with water, and optionally add a pH adjuster and an osmotic pressure adjuster. (b) The step of adding polyethylene glycol 4000, (c)((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate is added to obtain a suspension, the pH is adjusted to 6.5-7.5, and the volume is adjusted to the final volume. (d) The step of grinding the above suspension in a planetary ball mill to obtain a final suspension.

[0079] In the method for preparing the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection preparation described in the present invention, wet grinding technology can be used, and the material of the grinding beads is zirconia, which has high compatibility.

[0080] The method for preparing the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation described in the present invention may further include a step of preparing a lyophilized formulation, the step of preparing the lyophilized formulation including a step of lyophilizing the final suspension. In some examples, the lyophilization includes cooling the final suspension to -30°C or below and drying the cooled final suspension to below 0°C. In some examples, the lyophilization of the final suspension is (1) A pre-freezing step including cooling the final suspension to -45°C, (2) An initial drying step in which the cooled final suspension is dried below 0°C, (3) A secondary drying step in which the cooled final suspension is dried at a temperature above 0°C to obtain a freeze-dried formulation of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate.

[0081] The present invention further provides the use of the aforementioned ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation in the preparation of drugs for treating Alzheimer's disease.

[0082] In the preparation of drugs for the treatment of Alzheimer's disease, the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation can be administered by intramuscular or subcutaneous injection. [Brief explanation of the drawing]

[0083] [Figure 1] This graph illustrates the relationship between the mean plasma concentration of memantine and time after injecting rats with the formulation of Example 13 of the present invention (samples from batches 01 and 02 of Example 13). [Figure 2] This is the in vitro dissolution profile of the sample from Example 13. [Figure 3] This graph illustrates the relationship between the mean plasma concentration of memantine and time after injecting rats with the samples from Example 14 of the present invention (samples 01 to 05 of Example 14). [Figure 4] This graph illustrates the relationship between the average plasma concentration of memantine and time after injecting dogs with the samples from Example 14 of the present invention (samples 06-10 of Example 14). [Modes for carrying out the invention]

[0084] The general methods of the embodiments of the present invention are as follows (1-6).

[0085] 1. Parameters of the particle size analyzer for the ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension: Instrument: Malvern Mastersizer 3000 particle size analyzer, Sampler: Hydro 3000SM(A), Particle refractive index: 1.436, Dispersant refractive index: 1.33, Dispersant: Purified water, Background measurement time: 12S, Sample measurement time: 10S, Shading degree: 10%~20%, Stirring speed: 2000 rpm, Analytical model: General purpose, Measurement range: 0.005~2000 μm, Particle absorptivity: 0.1, Measurement was repeated 3 times and the average value was calculated.

[0086] 2. Zeta potential measurement of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension: Using a Malvern nanoparticle size potential analyzer, the sample was diluted 300-fold with purified water, and the measurement was repeated three times to obtain the average value.

[0087] 3. Parameters of the viscosity measuring instrument for the suspension of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate: Sampler: Modular rheometer, Sample measurement time: 4 min, Stirring speed: 2000 rpm, Distance between plate and sample: 0.2 mm, Measurement jig: PP-50, Analysis model: General purpose, Measurement range: 0~100001 / s.

[0088] 4. The content of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate and related substances: Instrument: High-performance liquid chromatograph (Agilent HPLC-DAD), Column chromatography: Waters Symmetry® C8, 4.6 × 100 mm, 3.5 μm, Detector: UV detector, detection wavelength 210 nm, Flow rate: 1.0 mL / min, Mobile phase A: Obtained by measuring 1 L of ultrapure water, adding 1 mL of phosphoric acid, and mixing uniformly, Mobile phase B: Acetonitrile, Diluent: Water:Acetonitrile = 30:70, Column temperature: 25 °C.

[0089] The gradient elution conditions for the content / related substances are as follows, with an execution time of 70 mins and an injection volume of 20 μl. [Table 1]

[0090] 5. Stability was considered, and the acceleration conditions were a temperature of 40°C and a relative humidity of 75%.

[0091] 6. The freeze-drying process parameters are shown in Table 1.

[0092] Table 1: Freeze-drying process parameters [Table 2]

[0093] Example 1: Investigation of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)methyl benzoate suspensions with different particle sizes Table 1-1: Prescription Form [Table 3]

[0094] Preparation process: (1) Dissolve the polysorbate 80 and span 20 of each batch in purified water at a rate of approximately 60% of the total volume, and stir until completely dispersed. (2) Add the prescribed amounts of polyethylene glycol 4000, anhydrous disodium hydrogen phosphate, and citric acid monohydrate, respectively, and stir until completely dissolved. (3) Under stirring conditions, gradually add the prescribed amount of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension, adjust the pH to 7.0-7.5 with sodium hydroxide, and bring to a final volume. (4) After grinding the above suspension, the particle size distribution, zeta potential, and viscosity of the ground suspension were measured.

[0095] Table 1-2 shows the particle size of the samples from each batch, Table 1-3 shows the zeta potential and viscosity, Table 1-4 shows the particle size after being left for 15 days under accelerated conditions, and Table 1-5 shows the related substances after being left for 15 days under accelerated conditions.

[0096] Table 1-2: Particle size (unit: μm) of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in the suspension of each batch after grinding. [Table 4]

[0097] Table 1-3: Zeta potential and viscosity of suspensions for each batch [Table 5]

[0098] According to the results in Tables 1-2 and 1-3, samples from each batch with different particle sizes of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles all formed suspensions that were highly fluid and injectable. Drug particles smaller than 1 μm may pose a risk of burst release, and suspension particles larger than 20 μm present problems related to needle passage during injection. Experimental results indicate that suspensions with good properties can be prepared when the particle size (D50) of the prepared suspension particles is in the range of 1 to 20 μm.

[0099] Table 1-4: Particle size analysis of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in suspensions of batches 01-04 left standing for 15 days under accelerated conditions (unit: μm) [Table 6]

[0100] Table 1-5: Investigation of related substances of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate in suspensions of batches 01-04 left standing for 15 days under accelerated conditions. [Table 7]

[0101] According to the results in Tables 1-4 and 1-5, after leaving samples from batches 01-04 under accelerated conditions for 15 days, there was no significant change in the particle size of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles and related substances in the suspension, indicating high stability.

[0102] Example 2: Investigation of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)methyl benzoate suspensions of different concentrations Table 2-1: Prescription Form [Table 8]

[0103] Preparation process: (1) Dissolve polysorbate 80 and span 20 in purified water at a rate of approximately 60% of the total volume, and stir until completely dispersed. (2) Add the prescribed amounts of polyethylene glycol 4000, anhydrous disodium hydrogen phosphate, and citric acid monohydrate, and stir until completely dissolved. (3) Under stirring conditions, gradually add the prescribed amount of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension, adjust the pH to 7.0-7.5, and bring to a final volume. (4) The above suspension was pulverized, and the particle size distribution, zeta potential, and viscosity of the pulverized suspension were measured.

[0104] The experimental results are shown in Tables 2-2 and 2-3.

[0105] Table 2-2: Particle size (unit: μm) of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in the suspension of each batch after grinding. [Table 9]

[0106] Table 2-3: Zeta potential and viscosity of suspensions for each batch [Table 10]

[0107] The results show that batches 01-07 all yielded suspensions with good properties. Considering that the maximum daily dose of memantine oral tablets is 20 mg and the maximum volume for intramuscular injection is 4 mL, the theoretical minimum dose that can be maintained for more than two weeks via intramuscular injection is 280 mg. Since the injection volume of all currently available sustained-release intramuscular injection formulations is less than 4 mL, the suspension content needs to exceed 70 mg / mL to obtain the theoretical dose that can be maintained for more than two weeks, and therefore batch 01 was discarded.

[0108] Example 3: Investigation of suspensions with different stabilizers Table 3-1: Prescription Form [Table 11]

[0109] Preparation process: (1) Disperse polysorbate 80, poloxamer 407, and polyoxyl 15 hydroxystearate in purified water at a rate of approximately 60% of the total volume, and stir until completely dispersed. (2) Under stirring conditions, gradually add the prescribed amount of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension, adjust the pH to 7.0-7.5, and bring to a final volume. (3) After grinding the above suspension, the particle size distribution, zeta potential, and viscosity of the ground suspension were measured.

[0110] The results are shown in Tables 3-2 and 3-3.

[0111] Table 3-2: Particle size (unit: μm) of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate in the suspension of each batch after grinding. [Table 12]

[0112] Table 3-3: Zeta potential and viscosity of suspensions from each batch after grinding. [Table 13]

[0113] The results show that using polysorbate 80, poloxamer 407, and polyoxyl 15-hydroxystearate as stabilizers allows for the preparation of suspensions with good properties.

[0114] Example 4: Investigation of suspensions with different stabilizers Table 4-1: Prescription Form [Table 14]

[0115] Preparation process: (1) Disperse polysorbate 80, polyoxyethylene hydrogenated castor oil RH40, polyoxyl castor oil EL35, and a mixture of polysorbate 80 and span 20 in purified water at a rate of approximately 60% of the total volume, and stir until completely dissolved. (2) Add the prescribed amounts of polyethylene glycol 4000, anhydrous disodium hydrogen phosphate, and citric acid monohydrate, respectively, and stir until completely dissolved. (3) Under stirring conditions, gradually add the prescribed amount of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension, adjust the pH to 7.0-7.5, and bring to a final volume. (4) After grinding the above suspension, the particle size distribution, zeta potential, and viscosity of the ground suspension were measured, and its stability was examined by leaving it to stand under accelerated conditions.

[0116] The results showed that the samples from batches 02 and 03 were discarded because, after grinding, they were highly viscous, contained a large amount of air bubbles, and could not form a fluid suspension, making them unsuitable for injection. The results for the remaining batches of samples are shown in Tables 4-2, 4-3, and 4-4.

[0117] Table 4-2: Particle size (unit: μm) of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in the suspension of each batch after grinding. [Table 15]

[0118] Table 4-3: Zeta potential and viscosity of suspensions from each batch after grinding. [Table 16]

[0119] Table 4-4: Examination of particle size of sample particles from batches 01 and 04 left for 15 days under accelerated conditions (unit: μm) [Table 17]

[0120] The results showed that using polysorbate 80 or a mixture of polysorbate 80 and span 20 as a stabilizer allowed for the preparation of suspensions with good properties, and the particle size remained virtually unchanged after being left for 15 days under accelerated conditions.

[0121] Example 5: Investigation of suspensions with different stabilizer dosages Table 5-1: Prescription Form [Table 18]

[0122] Preparation process: (1) Dissolve polysorbate 80 and Span 20 of different concentrations in purified water at approximately 60% of the total volume, and stir until completely dispersed. (2) Add the prescribed amount of polyethylene glycol 4000 and stir until completely dissolved. (3) Under stirring conditions, gradually add the prescribed amount of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension, adjust the pH to 7.0-7.5 with sodium hydroxide, and bring to a final volume. (4) After grinding the above suspension, the particle size distribution of the ground suspension was measured.

[0123] During the experiment, the sample from batch 05 was discarded because, after grinding, the suspension was found to be paste-like and unable to form a fluid suspension, making it unsuitable for injection. The results for the other batches are shown in Table 5-2. Table 5-2: Particle size (unit: μm) of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in the suspension of each batch after grinding. [Table 19]

[0124] The results show that samples from batches 01 to 04 all form highly fluid and injectable suspensions. Considering safety issues when injecting into the human body, the dose of stabilizer should not be too high. If the dose of stabilizer is too high, it will have a solubilizing effect on ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate, which may lead to burst release when injected into the human body. Therefore, in this invention, the concentration range of the stabilizer is set to 5 mg / mL to 48 mg / mL.

[0125] Example 6: Investigation of suspensions with different stabilizer dosages Table 6-1: Prescription Form [Table 20]

[0126] Preparation process: (1) Dissolve polysorbate 80 and Span 20 of different concentrations in purified water at approximately 60% of the total volume, and stir until completely dispersed. (2) Add the prescribed amount of polyethylene glycol 4000, anhydrous disodium hydrogen phosphate, and citric acid monohydrate, and stir until completely dissolved. (3) Under stirring conditions, gradually add the prescribed amount of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension, adjust the pH to 7.0-7.5, and bring to a final volume. (4) After grinding the above suspension, the particle size distribution, zeta potential, and viscosity of the ground suspension were measured to detect related substances, and the stability for 15 and 30 days was examined by leaving it to stand under accelerated conditions.

[0127] The particle size of the samples from each batch is shown in Table 6-2, the zeta potential and viscosity are shown in Table 6-3, the particle size after being left for 15 days under accelerated conditions is shown in Table 6-4, and the particle size after being left for 30 days under accelerated conditions is shown in Table 6-5.

[0128] Table 6-2: Particle size (unit: μm) of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in the suspension of each batch after grinding. [Table 21]

[0129] Table 6-3: Zeta potential and viscosity of suspensions for each batch [Table 22]

[0130] According to the results in Tables 6-2 and 6-3, all of the samples from batches 01 to 07 can form suspensions that are highly fluid and highly injectable.

[0131] Table 6-4: Particle size analysis of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in suspensions of several batches left standing for 15 days under accelerated conditions (unit: μm) [Table 23]

[0132] Table 6-5: Particle size analysis of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in suspensions of several batches left standing for 30 days under accelerated conditions (unit: μm) [Table 24]

[0133] According to the results in Tables 6-4 and 6-5, after leaving several batches of samples under accelerated conditions for 15 or 30 days, there was no significant change in the particle size of the ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in the suspension, indicating high stability.

[0134] Example 7: Investigation of suspensions with different suspending agents Table 7-1: Prescription Form [Table 25]

[0135] Preparation process: (1) Dissolve polysorbate 80 and span 20 in purified water at a rate of approximately 60% of the total volume, and stir until completely dispersed. (2) Add the prescribed amounts of polyethylene glycol 1000, polyethylene glycol 4000, polyethylene glycol 3350, polyvinylpyrrolidone K12, carboxymethylcellulose sodium 7L2P, anhydrous disodium hydrogen phosphate, and citric acid monohydrate, and stir until completely dissolved. (3) Under stirring conditions, gradually add the prescribed amount of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension, adjust the pH to 7.0-7.5, and bring to a final volume. (4) After grinding the above suspension, the particle size distribution, zeta potential, and viscosity of the ground suspension were measured.

[0136] During the experiment, the sample from batch 04 was discarded after being found to have many air bubbles, low fluidity, and unsuitable for injection after being crushed. The results of the remaining batches of samples are shown in Tables 7-2 and 7-3.

[0137] Table 7-2: Particle size (unit: μm) of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-6 methyl benzoate particles in the suspension of each batch after grinding. [Table 26]

[0138] Table 7-3: Zeta potential and viscosity of suspensions for each batch [Table 27]

[0139] The results show that using appropriate amounts of polyethylene glycol 3350, polyethylene glycol 4000, polyvinylpyrrolidone K30, or carboxymethylcellulose sodium 7L2P as suspension agents allows for the preparation of suspensions with good properties.

[0140] Example 8: Investigation of suspensions with different dosages of polyethylene glycol 4000 Table 8-1: Prescription Form [Table 28]

[0141] Preparation process: (1) Dissolve the polysorbate 80 and span 20 of each batch in purified water at a rate of approximately 60% of the total volume, and stir until completely dispersed. (2) Add the prescribed amounts of polyethylene glycol 4000, anhydrous disodium hydrogen phosphate, and citric acid monohydrate, respectively, and stir until completely dissolved. (3) Under stirring conditions, gradually add the prescribed amount of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension, adjust the pH to 7.0-7.5, and bring to a final volume. (4) After grinding the above suspension, the particle size distribution, zeta potential, and viscosity of the ground suspension were measured to detect related substances, and the stability was examined by leaving it to stand under accelerated conditions.

[0142] The results for each batch of samples are shown in Tables 8-2, 8-3, 8-4, and 8-5.

[0143] Table 8-2: Particle size (unit: μm) of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in the suspension of each batch after grinding. [Table 29]

[0144] Table 8-3: Zeta potential and viscosity of suspensions for each batch [Table 30]

[0145] According to the results in Tables 8-2 and 8-3, all of the samples from batches 01 to 05 can form suspensions that are highly fluid and highly injectable.

[0146] Table 8-4: Particle size analysis of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in suspensions of batches 02-05 left standing for 15 days under accelerated conditions (unit: μm) [Table 31]

[0147] The results showed that after being left for 15 days under accelerated conditions, aggregates formed in the 02 batch suspension with a polyethylene glycol 4000 concentration of 20 mg / mL, while there was no significant change in particle size in the 02-05 batch suspensions.

[0148] Table 8-5: Results for the relevant substances of batches 02-05 after being left for 15 days under accelerated conditions. [Table 32]

[0149] The results showed no significant changes in the relevant substances in the suspensions of batches 02-05 after being left for 15 days under accelerated conditions.

[0150] Example 9: Investigation of suspensions with different pH adjusters Table 9-1: Prescription Form [Table 33]

[0151] Preparation process: (1) Dissolve the polysorbate 80 and span 20 of each batch in purified water at a rate of approximately 60% of the total volume, and stir until completely dispersed. (2) Add the prescribed amounts of polyethylene glycol 4000, anhydrous disodium hydrogen phosphate, and citric acid monohydrate, respectively, and stir until completely dissolved. (3) Under stirring conditions, gradually add the prescribed amount of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension, adjust the pH to 7.0-7.5, and bring to a final volume. (4) After grinding the above suspension, the particle size distribution, zeta potential, and viscosity of the ground suspension were measured.

[0152] The experimental results are shown in Tables 9-2 and 9-3.

[0153] Table 9-2: Particle size (unit: μm) of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in the suspension of each batch after grinding. [Table 34]

[0154] Table 9-3: Zeta potential and viscosity of suspensions from each batch after grinding. [Table 35]

[0155] According to the results in Tables 9-2 and 9-3, all samples from batches 01 to 03 can form suspensions that are highly fluid and highly injectable.

[0156] Example 10: Investigation of suspensions with different dosages of pH adjuster Table 10-1: Prescription Form [Table 36]

[0157] Preparation process: (1) Dissolve the polysorbate 80 and span 20 of each batch in purified water at a rate of approximately 60% of the total volume, and stir until completely dispersed. (2) Add the prescribed amounts of polyethylene glycol 4000, anhydrous disodium hydrogen phosphate, and citric acid monohydrate, respectively, and stir until completely dissolved. (3) Under stirring conditions, gradually add the prescribed amount of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension, adjust the pH to 7.0-7.5, and bring to a final volume. (4) After grinding the above suspension, the particle size distribution, zeta potential, and viscosity of the ground suspension were measured.

[0158] The experimental results are shown in Tables 10-2 and 10-3.

[0159] Table 10-2: Particle size (unit: μm) of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in the suspension of each batch after grinding. [Table 37]

[0160] Table 10-3: Zeta potential and viscosity of suspensions from each batch after grinding. [Table 38]

[0161] Example 11: Investigation of different freeze-dried powders as freeze-drying protective agents Table 11-1: Prescription Form [Table 39]

[0162] Preparation process: (1) Dissolve the polysorbate 80 and span 20 of each batch in purified water at a rate of approximately 60% of the total volume, and stir until completely dispersed. (2) Add the prescribed amounts of mannitol, sorbitol, glucose, sucrose, polyethylene glycol 3350, polyethylene glycol 4000, anhydrous disodium hydrogen phosphate, and citric acid monohydrate, respectively, and stir until completely dissolved. (3) Under stirring conditions, gradually add the prescribed amount of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension, adjust the pH to 7.0-7.5 with sodium hydroxide, and bring to a final volume. (4) After grinding the above suspension, measure the particle size distribution of the ground suspension. (5) The pulverized suspension was filled into 10 mL vials, the fill volume was reduced to 5.6 mL, and it was freeze-dried. The particle size, zeta potential, and viscosity of the suspension after freeze-drying and redissolution were measured. The freeze-dried formulation was left to stand under accelerated conditions for 30 days, and the particle size and related substances of the suspension after redissolution of the freeze-dried formulation were examined.

[0163] The experimental results are shown in Tables 11-2, 11-3, 11-4, 11-5, and 11-6.

[0164] Table 11-2: Particle size (unit: μm) of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in the suspension of each batch after grinding. [Table 40]

[0165] Table 11-3: Particle size (unit: μm) of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in suspension redissolved after freeze-drying. [Table 41]

[0166] Table 11-4: Zeta potential and viscosity of suspensions redissolved after freeze-drying. [Table 42]

[0167] The results showed no significant change in particle size before and after lyophilization of the two batches of samples.

[0168] Table 11-5: Particle size (unit: μm) of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate particles in a suspension obtained by redissolving a lyophilized formulation after leaving it to stand under accelerated conditions for 30 days. [Table 43]

[0169] Table 11-6: Results of related substances in suspensions obtained by leaving lyophilized formulations under accelerated conditions for 30 days and then redissolving them. [Table 44]

[0170] The results showed that when polyethylene glycol 3350 or polyethylene glycol 4000 was used as a freeze-drying protective agent, the suspensions, after being pulverized, were free from process impurities, and after being left for 30 days under accelerated conditions, there were no significant changes in the particle size or related substances of the redissolved suspensions.

[0171] Example 12: Investigation of lyophilized formulations with different dosages of lyophilized protective agent. Table 12-1: Prescription Form [Table 45]

[0172] Preparation process: (1) Dissolve the polysorbate 80 and span 20 of each batch in purified water at a rate of approximately 60% of the total volume, and stir until completely dispersed. (2) Add the prescribed amounts of polyethylene glycol 4000, anhydrous disodium hydrogen phosphate, and citric acid monohydrate, respectively, and stir until completely dissolved. (3) Under stirring conditions, gradually add the prescribed amount of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension, adjust the pH to 7.0-8.0 with sodium hydroxide, and bring to a final volume. (4) After grinding the above suspension, measure the particle size distribution, zeta potential and viscosity of the grinding suspension. The pulverized suspension was filled into a 10 mL vial with a filling volume of 5.6 mL, freeze-dried, the particle size of the suspension redissolved after freeze-drying was measured, and then the freeze-dried preparation was left for 30 days under accelerated conditions, and the particle size and related substances of the suspension obtained by redissolving the freeze-dried preparation were examined.

[0173] The experimental results are shown in Table 12-2, Table 12-3, Table 12-4, Table 12-5 and Table 12-6.

[0174] Table 12-2: Particle size (unit: μm) of methyl ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate particles in the suspension of each batch after pulverization [Table 46]

[0175] Table 12-3: Results of zeta potential and viscosity of the suspension of each batch after pulverization [Table 47]

[0176] Table 12-4: Particle size (unit: μm) of methyl ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate particles in the suspension redissolved after freeze-drying [Table 48]

[0177] According to the results, there was no obvious change in the particle size of the samples of batches 01-05 before and after freeze-drying.

[0178] Table 12-5: Particle size (unit: μm) of methyl ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate particles in the suspension redissolved after leaving the freeze-dried preparation for 30 days under accelerated conditions [Table 49]

[0179] Table 12-6: Results of related substances in suspensions obtained by leaving lyophilized formulations to stand under accelerated conditions for 30 days and then redissolving them. [Table 50]

[0180] The results showed that none of the suspensions from batches 02-05 were introduced with process impurities after grinding, and there were no significant changes in the particle size or associated substances of the redissolved suspensions after being left to stand for 30 days under accelerated conditions.

[0181] Example 13: Pharmacokinetic study of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection in rats Table 13-1: Prescription Form [Table 51]

[0182] Preparation process: (1) Dissolve the polysorbate 80 and span 20 of each batch in purified water at a rate of approximately 60% of the total volume, and stir until completely dispersed. (2) Add the prescribed amounts of polyethylene glycol 4000, anhydrous disodium hydrogen phosphate, and citric acid monohydrate, respectively, and stir until completely dissolved. (3) Under stirring conditions, gradually add the prescribed amount of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension, adjust the pH to 7.0-8.0, and bring to a final volume. (4) After grinding the above suspension, measure the particle size distribution of the ground suspension. (5) The pulverized suspension was filled into a 10 mL vial, with a filling volume of 5.6 mL, freeze-dried, and the particle size of the suspension obtained by redissolving the freeze-dried preparation was measured.

[0183] The experimental results are shown in Table 13-2 and Table 13-3.

[0184] Table 13-2: Particle size of methyl ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate particles in the suspension before freeze-drying (unit: μm)

Table 52

[0185] Table 13-3: Particle size of methyl ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate particles in the suspension redissolved after freeze-drying (unit: μm)

Table 53

[0186] According to the results, the particle sizes of the suspension before freeze-drying and the suspension redissolved after freeze-drying are very close.

[0187] Pharmacokinetic studies were conducted in rats using samples from batches 01 and 02: Methyl ((((1R,3R,5S,7R)-�̀-dimethyladamantan-1-yl)carbamoyl)oxy)-benzoate aqueous suspension was administered by intramuscular injection at 75 mg / kg. Whole blood was collected before administration and at 0.25 h, 1 h, 2 h, 5 h, 7 h, 24 h, 48 h, 72 h, 96 h, 120 h, 140 h, and 170 h after administration. The whole blood was centrifuged at 12,000 revolutions per minute for 2 minutes to separate plasma, and the plasma was stored at -20 °C or -70 °C until LC / MS / MS analysis was performed.

[0188] The LC / MS / MS analysis parameters are as follows: Table 13-4: [Table 54]

[0189] The analysis was performed by injecting 20 μL of sample into a Waters Xbridge C18, 2.1 × 50 mm, 2.7 μM column. Analytical conditions: Mobile phases were 2 mM ammonium formate + 0.1% formic acid (A) and methanol + 2 mM ammonium formate + 0.1% formic acid (B). Flow rate was 0.4 mL / min.

[0190] The moving phase gradient is shown in Table 13-5. Table 13-5: [Table 55]

[0191] Tables 13-16 show the pharmacokinetic data of the formulation of Example 13 in rats. The compound of the present invention has excellent pharmacokinetic properties. Figure 1 shows the average drug-time curve in rats after intramuscular injection.

[0192] As shown in Figure 1, the ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)methyl benzoate suspensions can sustainably release the drug after administration and maintain it within a specific concentration range. The ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)methyl benzoate suspensions prepared in this invention have a clear sustained-release effect within one week or at least one week.

[0193] Table 13-6: Pharmacokinetic data in rats [Table 56]

[0194] Example 14: Pharmacokinetic studies of ((((1R,3R,5S,7R)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection in rats and dogs Table 14-1: Prescription Form [Table 57]

[0195] Preparation method: Polysorbate 80 and Span 20 were dissolved in approximately 60% of the total volume of sterile water for injection and stirred until completely dispersed. The prescribed amounts of polyethylene glycol 4000, anhydrous disodium hydrogen phosphate, and citric acid monohydrate were added and stirred until completely dissolved. Under stirring conditions, the prescribed amount of ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate was gradually added to obtain a ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate suspension, which was then brought to a final volume. The suspension was crushed and filled into 10 mL vials, the volume was reduced to 5.6 mL, and the vials were freeze-dried.

[0196] The obtained freeze-dried powder was redissolved in water and then its particle size was measured. The particle sizes were 1.516 μm for Dv10, 4.731 μm for Dv50, 11.953 μm for Dv90, 33.017 μm for Dv99, and 6.290 μm for Dv4 and Dv3, with a content of 115%.

[0197] The freeze-dried powder obtained in Example 14 was redissolved in 2.4 g of water, and then an in vitro dissolution experiment was performed. The dissolution method was the paddle method, the dissolution medium was a 0.5% sodium dodecyl sulfate solution, the rotation speed was 50 rpm, and the temperature was 30°C. The in vitro dissolution profile is shown in Figure 2.

[0198] The lyophilized formulation obtained in Example 14 was redissolved in 2.4 g of sterile water for injection to obtain a suspension of methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate at a concentration of 200 mg / mL, and pharmacokinetic studies were conducted in rats and dogs using this suspension. Solutions of 2.0 mg / mL and 4.0 mg / mL prepared using memantine hydrochloride and sterile water for injection were administered orally to control groups. The dosage groups for rats and dogs are shown in Tables 14-2 and 14-3, respectively. Each rat group consisted of 4 males and 4 females, for a total of 8 rats, and each dog group consisted of 5 males and 5 females, for a total of 10 dogs.

[0199] Table 14-2: Rat Dosage Design Table [Table 58]

[0200] Table 14-3: Dog Dosage Design Chart [Table 59]

[0201] Time of blood sample collection: Examples 14-01 / 14-02 / 14-06 / 14-07: Before administration and 0.5h, 1h, 2h, 4h, 6h, 8h, 24h after administration. Examples 14-03 / 14-04 / 14-05 / 14-08 / 14-09 / 14-10: Before administration and 1h, 4h, 8h, 24h, 48h, 72h, 96h, 120h, 144h, 192h, 264h, 312h after administration.

[0202] Blood sample detection method: 100 μL of Protease Inhibitor Cocktail (20×) was added to 1 mL of whole blood, and the mixture was inverted to ensure uniform mixing. The whole blood sample was placed in an ice bath before centrifugation and centrifuged at 1800 × g at 4°C for 10 minutes within 1 hour to separate the plasma under ice bath conditions. The concentration of the active compound 1-amino-3,5-dimethyladamantylamine in the blood sample at each time point was detected by LC-MS / MS. The analytical LC / MS / MS system included an LC-30 ultrafast liquid chromatograph and a Qtrap-5500 ion trap mass spectrometer, with a dryer temperature of 550°C, a dry gas flow rate of 9 L / min, a nebulizer pressure of 40 psi, and a capillary voltage of 3500 V. Quantitative analysis was performed in MRM mode. The parameters for MRM conversion are shown in Table 14-4. The analysis was carried out by injecting 1 μL of sample into a Waters Xbridge C18, 2.1 × 50 mm, 2.7 μM column. Analytical conditions: The mobile phase was 0.1% formic acid (A) and methanol (B). The flow rate was 0.45 mL / min. The mobile phase gradient is shown in Table 14-5.

[0203] Table 14-4: Parameters of Mass Spectrometry (MRM) [Table 60]

[0204] Table 14-5: Moving Phase Gradient [Table 61]

[0205] The drug blood concentration-time curves in rats after administration are shown in Figure 3, and the pharmacokinetic data are shown in Table 14-6. The drug blood concentration-time curves in dogs after administration are shown in Figure 4, and the pharmacokinetic data are shown in Table 14-7.

[0206] Table 14-6: Pharmacokinetic data of memantine in rats after single administration. [Table 62]

[0207] Table 14-7: Pharmacokinetic data of memantine in dogs after single administration. [Table 63]

[0208] According to the pharmacokinetic data from rats and dogs, oral administration involves a much lower dose than intramuscular injection, but its Cmax is still much greater than that after intramuscular injection. In contrast, after oral administration, the drug blood concentration rapidly reaches its peak and then rapidly decreases. The present invention's ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate injection formulation can maintain the drug blood concentration at or above the trough concentration after oral administration for at least two weeks, demonstrating that the sustained-release intramuscular injection avoids the "peak-trough" phenomenon of drug blood concentration and allows for a reduction in administration frequency to once every two weeks.

[0209] In the description of the specification of the present invention, any description referring to the terms "several examples," "several embodiments," "specific examples," or "several examples" means that the specific features, structures, materials, or properties described with reference to such examples are included in at least one example of the present invention. In this specification, exemplary expressions of the above terms do not necessarily mean the same examples. Furthermore, the specific features, structures, materials, or properties described can be combined in an appropriate manner in any one or more examples. Also, as long as they do not conflict with each other, those skilled in the art can combine and combine different examples and features of different examples described herein.

[0210] Although embodiments of the present invention have been shown and described above, these embodiments are merely illustrative and should not be understood as limiting the present invention. Those skilled in the art can modify, alter, substitute, and transform the above embodiments within the scope of the present invention.

Claims

1. A formulation comprising ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate, wherein the Dv50 of the ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate formulation is 1.0 μm to 10.0 μm, (a) Methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)benzoate, which has a concentration range of 125.0 mg / mL to 250.0 mg / mL, (b) A mixture of polysorbate 80 and span 20 having a concentration range of 6.0 mg / mL to 20.0 mg / mL, wherein the ratio of the concentrations of polysorbate 80 and span 20 is polysorbate 80:span 20 = 2:1 to 4:1, (c) A formulation comprising polyethylene glycol 4000 having a concentration range of 80.0 mg / mL to 120.0 mg / mL.

2. The formulation according to claim 1, further comprising a pH adjusting agent.

3. The formulation according to claim 2, wherein the pH adjusting agent comprises at least one selected from hydrochloric acid, sodium hydroxide, acetic acid, phosphoric acid and its salts, tartaric acid and its salts, acetic acid and its salts, citric acid and its salts, carbonate and its salts, and citric acid and its salts.

4. (a) ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate, (b) A carrier and, optionally, (c) The formulation according to claim 1, comprising water for injection.

5. (a) Methyl ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)benzoate, which has a concentration range of 125.0 mg / mL to 250.0 mg / mL, (b) A carrier and, optionally, (c) Water for injection, and The formulation according to claim 1, wherein memantine is continuously released for a period of at least one week.

6. The formulation according to any one of claims 1 to 5, wherein the pH range is 6.0 to 9.

0.

7. A formulation according to any one of claims 1 to 6, wherein memantine is continuously released for a period of at least one week after injection.

8. The preparation according to any one of claims 1 to 7, which is a liquid injection preparation or a lyophilized preparation that is ready for immediate use.

9. (a) A step of mixing a mixture of polysorbate 80 and span 20 with water and adding polyethylene glycol 4000, (b) Adding ((((1r,3R,5S,7r)-3,5-dimethyladamantan-1-yl)carbamoyl)oxy)-methyl benzoate to obtain a suspension, (c) Optionally, adjust the pH with a pH adjuster to bring the volume to a fixed level. (d) A method for preparing a pharmaceutical product according to any one of claims 1 to 8, comprising the step of grinding the suspension to obtain a final suspension.

10. The method according to claim 9, further comprising the step of preparing a lyophilized formulation, wherein the step comprises lyophilizing the final suspension.

11. Use of the formulation according to any one of claims 1 to 8 in the preparation of a drug for treating Alzheimer's disease.

Images